Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering
Galmed listed on Nasdaq in 2014. The company's stock jumped around 125% over the past two weeks following a successful study
Nasdaq-listed Galmed Pharmaceuticals Ltd. is looking to raise $75 million in an underwritten offering of public shares, the company announced Monday. Israel-based, clinical-stage Galmed develops a once-daily oral therapy for liver diseases. The company intends to use the proceeds for clinical and business development and for general corporate purposes. The company's stock jumped around 125% over the past two weeks after it announced a successful study on June 11.